The Financial Associated Press (Shanghai, researcher Yao Hui) reported that a week after trading suspension, Tuoxin Pharmaceutical, known as the “new crown magic drug stock”, issued an announcement on Friday evening regarding the results of the stock suspension verification and the resumption of trading, saying that the company is not in Merck’s company. In the list of qualified suppliers, no cooperation agreement has been signed with Merck, and there is no cooperative relationship with Merck, and no uridine products have been supplied to Merck.
In the 6 trading days before the suspension, Tuoxin Pharmaceutical had a 5-day 20% daily limit, and the cumulative increase was as high as 185%. The analysis believes that the previous surge in Tuoxin Pharmaceutical’s share price is related to the news of Merck’s latest approved “New Crown Medicine”.
Since the end of October, investors have constantly asked Tuoxin Pharmaceuticals, “I heard that the company has supplied the bulk of Merck’s world’s first anti-coronavirus oral drug Molnupiravir. Is it true?” Tuoxin Pharmaceutical’s answer is, “ The company’s uridine is exported through traders. “The company provides uridine, the raw material of EIDD-2801, which is the raw material for the production of the new crown oral drug Molnupiravir.” It did not specify whether the company has supplied Merck.
It is understood that Merck is one of the leading pharmaceutical companies in the field of oncology and HPV drugs. On November 4, Merck’s new crown oral drug Molnupiravir (Molnupiravir) was approved for marketing in the UK. The drug is the world‘s first oral antiviral drug approved for the treatment of mild to moderate COVID-19 in adults.
It is worth noting that Tuoxin Pharmaceutical, which was recently listed, is not covered by securities firm research reports. What is the sacred fund behind the hype? The data of the Dragon and Tiger List released after the market on November 12 showed that there are many active hot money behind the speculation, and another institution is ranked to buy a seat.
According to the Shenzhen Stock Exchange’s disclosure on November 12, Tuoxin Pharmaceuticals acquired 73.06% of total purchases by natural persons from November 5 to November 12, among which small and medium-sized investors accounted for 1.699 billion yuan. 40.44%, accounting for 26.94% of institutional purchases.
In addition to Tuoxin Pharmaceuticals, a number of companies have recently clarified rumors about new crown oral drugs with Pfizer and Merck, including Chengyi Pharmaceuticals, Jianfeng Group and Tianyu.
Since November, many investors have consulted Chengyi Pharmaceuticals, “Is the nucleoside raw materials uridine and cytidine produced by the company provided to Pfizer and Merck to become the raw materials for the production of new crown oral drugs?” Chengyi Pharmaceuticals replied, ” The company has the production conditions for adenosine and uridine, and currently it has not exported or sold to Pfizer or Merck’s new crown.
Fusion MediaOr anything withFusion MediaThe person concerned does not accept any liability for loss or damage caused by relying on the data, quotations, charts and buy/sell signals contained in this website. Please fully understand the risks and costs associated with financial market transactions. This is one of the most risky forms of investment. The English version of this agreement is the main version. If there is a discrepancy between the English version and the Chinese version, the English version shall prevail.